Quantum BioPharma
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
NASDAQ: QNTM | CSE: QNTM | FRA: 0K91 Overview Quantum BioPharma Ltd. announced its financial and operational results for the second quarter of 2026, ended June 30, 2026, according to the company. As of June 30, 2026, the company's combined cash and cash equivalents, and digital assets, totaled approximately US$